UK biotechnology company Immunocore on Thursday said it has secured private financing worth $320 million (£205 million) from investors including US drug-major Eli Lilly (NYSE: LLY) and UK-based asset manager Neil Woodford’s eponymous firm Woodford Investment Management.
This was described as Europe’s largest private life sciences financing.
The Oxford-based company, in a statement said the funds will be used to accelerate its pipeline of Immune mobilising mTCR Against Cancer (ImmTACs), a novel T-cell receptor drug. ImmTACs have the potential to treat a broad range of solid tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze